Literature DB >> 18655783

Blockade of anaesthetic-induced preconditioning in the hyperglycaemic myocardium: the regulation of different mitogen-activated protein kinases.

Nina C Weber1, Christine Goletz, Ragnar Huhn, Yvonne Grueber, Benedikt Preckel, Wolfgang Schlack, Dirk Ebel.   

Abstract

Preconditioning by volatile anaesthetics is blocked by hyperglycaemia. The regulation of mitogen-activated protein kinases during this effect has yet not been investigated. For infarct size measurements, anaesthetized rats were subjected to 25 min coronary artery occlusion followed by 120 min reperfusion. Control animals were not further treated. One group was preconditioned by two 5-min periods of desflurane inhalation (desflurane preconditioning, Des-preconditioning, 1MAC), each followed by 10-min washout. Four groups received glucose 50% in order to achieve blood glucose concentrations between 22.2 and 33.3 mM/l. Glucose infusion started 40 min before ischaemia (early hyperglycaemia, EH) and stopped with the onset of artery occlusion with (EH+Des-preconditioning) or without (EH) preconditioning. The other two groups received glucose during ischaemia (late hyperglycaemia, LH), again with (LH+Des-preconditioning) or without (LH) preconditioning. Additional hearts were excised for Western blot of mitogen-activated protein kinases. Infarct size was reduced from 51.7+/-9.0% in controls to 28.8+/-11.8% after Des-preconditioning (P<0.01 vs Con). Hyperglycaemia alone did not affect infarct size (EH, 51.5+/-9.0%, LH, 44.3+/-16.9%), but EH as well as LH blocked Des-preconditioning (49.1+/-12.3%, P<0.01, 48.1+/-17.6%, P<0.05 vs Des-preconditioning). All three mitogen-activated protein kinases showed a similar time course pattern of phosphorylation in the Des-preconditioning, EH and EH+Des-preconditioning group. Despite the lack of cardioprotection, mitogen-activated protein kinases are activated in hyperglycaemic myocardium. Therefore, it can be assumed that the hyperglycaemic induced blockade of Des-preconditioning is situated downstream or in parallel of these mitogen-activated protein kinases or involves different signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18655783     DOI: 10.1016/j.ejphar.2008.07.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Noble gases as cardioprotectants - translatability and mechanism.

Authors:  Kirsten F Smit; Nina C Weber; Markus W Hollmann; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 2.  Anaesthetics as cardioprotectants: translatability and mechanism.

Authors:  C Kikuchi; S Dosenovic; M Bienengraeber
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 3.  Diabetic cardiomyopathy: pathophysiology and clinical features.

Authors:  Takayuki Miki; Satoshi Yuda; Hidemichi Kouzu; Tetsuji Miura
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 4.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

Review 5.  [Perioperative cardioprotection - From bench to bedside : Current experimental evidence and possible reasons for the limited translation into the clinical setting].

Authors:  Carolin Torregroza; Sebastian Roth; Katharina Feige; Giovanna Lurati Buse; Markus W Hollmann; Ragnar Huhn
Journal:  Anaesthesist       Date:  2021-01-19       Impact factor: 1.041

Review 6.  Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.

Authors:  Charissa E van den Brom; Carolien Se Bulte; Stephan A Loer; R Arthur Bouwman; Christa Boer
Journal:  Cardiovasc Diabetol       Date:  2013-03-04       Impact factor: 9.951

7.  Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning.

Authors:  Tamás Baranyai; Csilla Terézia Nagy; Gábor Koncsos; Zsófia Onódi; Melinda Károlyi-Szabó; András Makkos; Zoltán V Varga; Péter Ferdinandy; Zoltán Giricz
Journal:  Cardiovasc Diabetol       Date:  2015-11-18       Impact factor: 9.951

8.  Acute hyperglycemia abolishes ischemic preconditioning by inhibiting Akt phosphorylation: normalizing blood glucose before ischemia restores ischemic preconditioning.

Authors:  Zequan Yang; Yikui Tian; Yuan Liu; Sara Hennessy; Irving L Kron; Brent A French
Journal:  Oxid Med Cell Longev       Date:  2013-11-25       Impact factor: 6.543

9.  Influence of Hyperglycemia on Dexmedetomidine-Induced Cardioprotection in the Isolated Perfused Rat Heart.

Authors:  Carolin Torregroza; Katharina Feige; Laura Schneider; Sebastian Bunte; Martin Stroethoff; André Heinen; Markus W Hollmann; Ragnar Huhn; Annika Raupach
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

Review 10.  Pharmacological Conditioning of the Heart: An Update on Experimental Developments and Clinical Implications.

Authors:  Sebastian Roth; Carolin Torregroza; Katharina Feige; Benedikt Preckel; Markus W Hollmann; Nina C Weber; Ragnar Huhn
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.